vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $185.1M, roughly 1.6× Doximity, Inc.). Doximity, Inc. runs the higher net margin — 33.3% vs 12.8%, a 20.4% gap on every dollar of revenue. On growth, Doximity, Inc. posted the faster year-over-year revenue change (9.8% vs -6.4%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 4.2%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
DOCS vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $295.9M |
| Net Profit | $61.6M | $38.0M |
| Gross Margin | 89.9% | 64.6% |
| Operating Margin | 38.9% | 18.4% |
| Net Margin | 33.3% | 12.8% |
| Revenue YoY | 9.8% | -6.4% |
| Net Profit YoY | -18.1% | 68.3% |
| EPS (diluted) | $0.31 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $295.9M | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $145.9M | $317.0M | ||
| Q1 25 | $138.3M | $316.2M | ||
| Q4 24 | $168.6M | $297.0M | ||
| Q3 24 | $136.8M | $289.5M | ||
| Q2 24 | $126.7M | $306.1M | ||
| Q1 24 | $118.1M | $303.4M |
| Q4 25 | $61.6M | $38.0M | ||
| Q3 25 | $62.1M | — | ||
| Q2 25 | $53.3M | $-17.7M | ||
| Q1 25 | $62.5M | $22.6M | ||
| Q4 24 | $75.2M | $34.9M | ||
| Q3 24 | $44.2M | $33.6M | ||
| Q2 24 | $41.4M | $40.6M | ||
| Q1 24 | $40.6M | $49.1M |
| Q4 25 | 89.9% | 64.6% | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | 62.7% | ||
| Q1 25 | 89.5% | 67.9% | ||
| Q4 24 | 91.6% | 65.3% | ||
| Q3 24 | 90.0% | 63.2% | ||
| Q2 24 | 89.3% | 66.4% | ||
| Q1 24 | 89.4% | 67.4% |
| Q4 25 | 38.9% | 18.4% | ||
| Q3 25 | 37.8% | — | ||
| Q2 25 | 37.4% | -7.5% | ||
| Q1 25 | 35.2% | 12.2% | ||
| Q4 24 | 47.4% | 16.0% | ||
| Q3 24 | 38.8% | 13.8% | ||
| Q2 24 | 36.4% | 15.0% | ||
| Q1 24 | 35.5% | 22.1% |
| Q4 25 | 33.3% | 12.8% | ||
| Q3 25 | 36.8% | — | ||
| Q2 25 | 36.5% | -5.6% | ||
| Q1 25 | 45.2% | 7.1% | ||
| Q4 24 | 44.6% | 11.7% | ||
| Q3 24 | 32.3% | 11.6% | ||
| Q2 24 | 32.7% | 13.3% | ||
| Q1 24 | 34.4% | 16.2% |
| Q4 25 | $0.31 | $0.24 | ||
| Q3 25 | $0.31 | — | ||
| Q2 25 | $0.27 | $-0.11 | ||
| Q1 25 | $0.31 | $0.14 | ||
| Q4 24 | $0.37 | $0.22 | ||
| Q3 24 | $0.22 | $0.21 | ||
| Q2 24 | $0.21 | $0.26 | ||
| Q1 24 | $0.20 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $979.3M | $2.0B |
| Total Assets | $1.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | $172.9M | ||
| Q3 25 | $169.2M | — | ||
| Q2 25 | $137.3M | $162.2M | ||
| Q1 25 | $209.6M | $140.7M | ||
| Q4 24 | $165.3M | $177.5M | ||
| Q3 24 | $184.2M | $187.5M | ||
| Q2 24 | $111.4M | $152.9M | ||
| Q1 24 | $96.8M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $979.3M | $2.0B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.1B | $2.0B | ||
| Q4 24 | $1.0B | $2.1B | ||
| Q3 24 | $961.2M | $2.1B | ||
| Q2 24 | $913.6M | $2.1B | ||
| Q1 24 | $901.4M | $2.0B |
| Q4 25 | $1.2B | $2.5B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.2B | $2.7B | ||
| Q3 24 | $1.1B | $2.7B | ||
| Q2 24 | $1.1B | $2.7B | ||
| Q1 24 | $1.1B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | — | ||
| Q3 25 | $93.9M | — | ||
| Q2 25 | $62.1M | $98.2M | ||
| Q1 25 | $98.5M | $41.1M | ||
| Q4 24 | $65.2M | $84.3M | ||
| Q3 24 | $68.3M | $63.9M | ||
| Q2 24 | $41.2M | $75.5M | ||
| Q1 24 | $63.9M | $81.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 3.2% | ||
| Q2 24 | 0.0% | 5.9% | ||
| Q1 24 | 0.0% | 5.4% |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | 1.82× | ||
| Q4 24 | 0.87× | 2.42× | ||
| Q3 24 | 1.55× | 1.90× | ||
| Q2 24 | 1.00× | 1.86× | ||
| Q1 24 | 1.57× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
